β-blocker therapy for infantile hemangioma

Area of Science:

• Vascular Biology
• Developmental Biology
• Pharmacology

Background:

• Infantile hemangioma (IH) affects 15% of infants, often requiring intervention for functional threats, ulceration, or distortion.
• Propranolol is the primary treatment for problematic IH, with other beta-blockers and ACE inhibitors explored as alternatives.

Purpose of the Study:

• To review the indications, dosing, efficacy, and adverse effects of propranolol for IH.
• To explore alternative therapeutic options for IH treatment.

Main Methods:

• Review of current literature on the biological origin and treatment of IH.
• Analysis of therapeutic alternatives including oral and topical beta-blockers and ACE inhibitors.

Main Results:

• The hemogenic endothelium origin of IH and its regulation by the renin-angiotensin system explain the accelerated involution induced by propranolol, beta-blockers, and ACE inhibitors.
• Various treatment regimens and alternatives like atenolol, acebutolol, nadolol, intralesional/topical propranolol, timolol, and captopril were examined.

Conclusions:

• Enhanced understanding of IH biology elucidates the mechanism of action for accelerated involution by propranolol, beta-blockers, and ACE inhibitors.
• Further research is needed to optimize dosing, duration, efficacy, and safety of alternative therapies.
• Non-beta-adrenergic actions of propranolol offer potential for targeted IH treatment with reduced side effects.